ライフサイエンスコーパス: tumor lysis syndrome

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 d glucuronide metabolite AUC correlated with tumor lysis syndrome.

2 ity using this novel schedule was hyperacute tumor lysis syndrome.

3 e aminotransferase, febrile neutropenia, and tumor lysis syndrome.

4 f management in diseases other than gout and tumor lysis syndrome.

5 ssociated with thrombocytopenia and, rarely, tumor lysis syndrome and cytokine release reactions; the

6 l monitoring and aggressive intervention for tumor lysis syndrome and hyperkalemia is necessary for s

7 s the use of urate oxidase for prevention of tumor lysis syndrome and the associated uric acid nephro

8 vel in vivo, with delayed development of the tumor lysis syndrome and with complete remission.

9 self, but complications such as leukostasis, tumor lysis syndrome, and disseminated intravascular coa

10 ti-CD19-CAR T cells, another CLL patient had tumor lysis syndrome as his leukemia dramatically regres

11 The tumor lysis syndrome developed in 1 patient; no treatmen

12 ts to the dose-escalation schedule, clinical tumor lysis syndrome did not occur in any of the 60 pati

13 on and kidney size, but a moderate degree of tumor lysis syndrome ensued.

14 zyme capable of treating gout and preventing tumor lysis syndrome in human patients.

15 Acute tumor lysis syndrome necessitates intravenous hydration,

16 Clinical tumor lysis syndrome occurred in 3 of 56 patients in the

17 Dose-limiting toxicity was acute tumor lysis syndrome resulting in fatal hyperkalemia.

18 Apart from the tumor lysis syndrome, the only other grade 3/4 toxic eff

19 ccur in four patients, as a result of severe tumor lysis syndrome; three of these patients required h

20 malignancy and were in danger of developing tumor lysis syndrome (TLS) and subsequent acute uric aci

21 Acute tumor lysis syndrome (TLS) is characterized by the triad

22 c malignancies at risk for hyperuricemia and tumor lysis syndrome (TLS) were randomly assigned to ras

23 yndrome was not observed, whereas laboratory tumor lysis syndrome was documented in three patients.

24 Clinical tumor lysis syndrome was not observed, whereas laborator

25 Tumor lysis syndrome was the dose-limiting toxicity (DLT

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。